Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Yasmin: the reason why.

I H Thorneycroft1

  • 1Mobile Ob-Gyn Center, Lunar Research and Department of Obstetrics and Gynecology, University of South Alabama College of Medicine, Alabama 36607, USA.

The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception
|March 28, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultra-low-dose oral contraceptives: are they right for your patient?

Medscape women's health·2002
Same author

Protecting the endometrium. Opposing the hyperplasia/malignancy potential of ERT.

The Journal of reproductive medicine·2001
Same author

Vaginal bleeding patterns in women receiving hormone replacement therapy. Impact of various progestogen regimens.

The Journal of reproductive medicine·2001
Same author

Effect of low-dose oral contraceptives on androgenic markers and acne.

Contraception·2000
Same author

Analysis of in vitro migration patterns of human spermatozoa by a petri dish-based horizontal column.

Biology of reproduction·1999
Same author

Cycle control with oral contraceptives: A review of the literature.

American journal of obstetrics and gynecology·1999
Same journal

Dissociation of gonadal and adrenal androgens one year after etonogestrel implant insertion.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2026
Same journal

A titrated low-dose misoprostol protocol for second-trimester abortion (13-26 weeks) in women with one prior cesarean and preterm premature rupture of membranes: a clinical practice report.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2026
Same journal

Factors associated with unplanned pregnancy among pregnant female adolescents in the Southeast region of Brazil: a cross-sectional study.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2026
Same journal

Contraceptive effectiveness of a digital contraceptive with a wearable device vs an oral thermometer.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2026
Same journal

Fertile-window misclassification in period-tracking applications and associated pregnancy risk: a large observational analysis.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2026
Same journal

Measurement of pain during first trimester medical abortion: an exploratory qualitative study.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2026
See all related articles

New oral contraceptives with drospirenone offer unique benefits beyond traditional contraception. Drospirenone-containing pills provide improved acne control, reduced fluid retention, and potential weight loss, enhancing user satisfaction and adherence.

Area of Science:

  • Reproductive Health
  • Pharmacology
  • Gynecology

Background:

  • Oral contraceptives (OCs) have evolved significantly over 40 years with dosage reductions and new progestogens.
  • High rates of unintended pregnancy and discontinuation due to side effects and misperceptions persist, especially in women over 35.
  • There is a need for OCs with novel progestogenic properties to improve efficacy and tolerability.

Purpose of the Study:

  • To evaluate the non-contraceptive benefits and efficacy of a new oral contraceptive containing drospirenone (DRSP/EE).
  • To assess the impact of drospirenone's unique antimineralocorticoid and antiandrogenic properties on OC users.
  • To compare the efficacy and side effect profile of DRSP/EE with a reference OC.

Main Methods:

  • Clinical evaluation of a drospirenone-containing oral contraceptive (3 mg drospirenone/30 microg ethinylestradiol).

Related Experiment Videos

  • Assessment of contraceptive efficacy using the corrected Pearl index.
  • Monitoring of non-contraceptive benefits including acne control, fluid retention, and weight changes.
  • Comparison with a reference oral contraceptive containing desogestrel.

    • Main Results:

    • The DRSP/EE oral contraceptive demonstrated excellent efficacy with a corrected Pearl index of 0.09.
    • Significant improvements were observed in acne control and reduction of fluid-related symptoms due to drospirenone's properties.
    • A notable weight loss was observed with DRSP/EE compared to the desogestrel-containing reference preparation.
    • Cycle control was excellent and comparable to other OCs.

    Conclusions:

    • The drospirenone-containing oral contraceptive (DRSP/EE) offers significant non-contraceptive benefits, including improved acne and reduced fluid retention.
    • Its potent progestogenic activity ensures high contraceptive efficacy and excellent cycle control.
    • DRSP/EE provides a valuable new option for women seeking enhanced satisfaction and additional health benefits from their oral contraceptive.